共 595 条
[1]
Xiong Y(2022)Pharmaceutical expenditure and total health-care expenditure in OECD countries and China: bidirectional Granger causality on the basis of health level Expert Rev Pharmacoecon Outcomes Res 22 502-512
[2]
Cui Y(2020)The impacts and unintended consequences of the nationwide pricing reform for drugs and medical services in the urban public hospitals in China BMC Health Serv Res 20 1058-10
[3]
Zhang X(2012)Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea Value Health 15 104-58
[4]
Zhang X(2020)Using strategic price negotiations to contain costs and expand access to medicines in China BMJ Glob Health 5 e002256-95
[5]
Lai H(2019)Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of Disease Study 2017 Lancet 394 1145-23
[6]
Zhang L(2020)Cancer burden in China: trends, risk factors and prevention Cancer Biol Med 17 879-51
[7]
He J(2006)Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model Ther Clin Risk Manag 2 317-97
[8]
Fu B(2021)Analysis of Launch and Postapproval Cancer Drug pricing, Clinical Benefit, and Policy Implications in the US and Europe JAMA Oncol 7 e212026-24
[9]
Jin C(2020)Formal implementation of cost-effectiveness evaluations in Japan: a Unique Health Technology Assessment System Value Health 23 43-60
[10]
Yim EY(2013)Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in dutch and swedish reimbursement decision making PharmacoEconomics 31 781-5